Kinetic Technologies Announces New IEEE® 802.3bt-Compliant Powered Device and DC-DC Flyback Controller Solution for PoE Power Supplies
15.11.2022 09:00:00 EET | Business Wire | Press release
Power management and video/audio interface IC leader Kinetic Technologies announced today the KTA1140 IEEE 802.3bt-compliant Powered Device Interface IC and the KTB1095 synchronous flyback control IC with integrated digital isolated feedback as the latest additions to their PoE and DC-DC Converter product lines.
Fully compliant with IEEE 802.3bt, 802.3at and 802.3af standards, the KTA1140 integrates input surge protection, a PD controller with 100V, low resistance 0.1Ω hot-swap MOSFET, which fully supports input power levels up to 90W. The PD controller also includes eight-event classification, ATDET, PD Detect, over temperature protection and under voltage lockout (UVLO). The KTA1140 is also designed to provide seamless support for local supplies down to 9.5V.
The KTB1095 is a highly integrated synchronous flyback converter with internal feedback utilizing a 3000VRMS digital isolator, designed to eliminate the need for an external opto-coupler, reducing cost and size. Operating over a wide operating voltage range from 5V to 100V, the KTB1095 includes both primary and secondary side, high current MOSFET drivers and employs current-mode constant on-time control for fast transient response. Featuring an adjustable soft-start function to limit start-up in-rush current, the KTB1095 also includes input voltage UVLO, output over-voltage-protection (OVP), cycle-by-cycle current limit, short-circuit protection and thermal shutdown.
“Our goal at Kinetic is to make it as easy as possible for our customers to design their power supplies,” said Erik Ogren, Kinetic Technologies’ Senior Director of Marketing. “The KTA1140 supports Class 8, 90W designs with its ultra-low resistance hot-swap MOSFET and simplifies system designs with local voltage support. KTB1095 takes advantage of Kinetic’s Tru-Iso™ technology to deliver integrated 3000V-rms on-chip digital isolator feedback, reducing BOM count and PCB area.”
KTA1140 and KTB1095 are sampling now, with production expected to begin in the first quarter of 2023.
Visit Kinetic Technologies for further information.
Key Product Highlights:
KTA1140 – PoE 802.3bt PD Interface
-
Fully supports IEEE® 802.3bt
- Input Power Levels Up to 90W
- Class 0-8 for PoE PD
- Compatible with IEEE® 802.3af/at
- IEC 61000-4-2/3/4/5/6 requirements for EMC
- Seamless support for local power down to 9.5V
- Programmable DC current limit
- Low resistance (typ. 0.1Ω) Hot Swap MOSFET
- 5x5 mm, 20 lead QFN Package
KTB1095 – 100V Synchronous Flyback Controller with Digital Isolation
- Wide 5V to 100V Operating Voltage Range
-
Integrated Digital Isolator Feedback
- 3000V-rms Integrated Isolation
- ±1% Voltage Reference
-
Integrated primary and secondary side MOSFET Drivers
- 3A Sink / 2A Source driving capability
- Adjustable Switching Frequency from 100kHz to 700kHz
- Integrated Protection: Cycle-by-cycle current limit, Input UVLO, OCP, SCP, TSP
- SOIC-16 Wide Body (10.3mm x 7.5mm) Package
About Kinetic Technologies
Kinetic Technologies is a global designer, developer, and provider of proprietary and innovative high-performance analog and mixed-signal semiconductor products for a wide variety of markets. Kinetic’s products help its customers efficiently regulate power, intelligently protect their devices from harmful voltage and current spikes, and deliver high-bandwidth, low-latency, and secured connectivity for video, display, and general-purpose applications.
For more information, please visit http://www.kinet-ic.com/.
*Kinetic Technologies’ logo is a trademark of Kinetic Technologies. All other brand and product names appearing in this document are the property of their respective holders.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221114005531/en/
Contact information
Robert Bendz
Phone: +1 -408-746-9000
Email: rbendz@kinet-ic.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 08:30:00 EEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
